More recently, the development of three FDA-approved second-generation AR antagonists, enzalutamide [4], apalutamide [5], and darolutamide [6] (Figure 2), has marked significant progress in the treatment of various stages of prostate cancer. This evidence concerns the gene AR and prostate carcinoma.